Sanofi

Open: 51.75 Close: 51.56 Change: -0.19

Stop waiting time to find out about Sanofi Company Inc Stock: Our AI summarizes all info about it.

The game is changing. There is a new strategy to evaluate Sanofi fundamental value, possible risks and most salient advantages. Investors have traditionally relied in reading large amounts of text to evaluate the fundamental value of a stock or company. However, the development of Artificial Intelligence (AI) tools is modifying the way investments are evaluated in markets. Today, machine learning, natural language processing and bigdata allow making this process automatic, reducing large amounts of text to the elements that have a higher activation in a neural network. We programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Sanofi are: Sanofi, Buy, expect, reach, annual, total, mn, and the …

Concept Map

Semantic Network

Stock Summary

Sanofi engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company also provides cough, cold.

Today's Summary

UBS analyst Jo Walton upgraded Sanofi ( SNYNF – Research Report ) to a Buy today and set a price target of €110.00. Jefferies Reaffirms Their Buy Rating on Sanofi.

Today's News

Revenue for Itepekimab is expected to reach an annual total of $81 mn by 2037 in the US based off GlobalDatas Expiry Model. Sanofi is a healthcare company engaged in the discovery, development, manufacturing, and marketing of medicines and vaccines. UBS analyst Jo Walton upgraded Sanofi ( SNYNF – Research Report ) to a Buy today and set a price target of €110.00. Sanofi has an average volume of 7,117.06, representing a 3.83% upside. Jefferies Reaffirms Their Buy Rating on Sanofi. Sanofi serves customers worldwide. Sanofi has provided financial and moral support to over 3,820 children around the world. Jefferies analyst Peter Welford maintained a Buy rating on Sanofi ( SNYNF – Research Report ) today and set a price target of €115.00. Sanofi considers entering the obesity market — sanofi – recognizing the people who taught us to never settle - youtube.com. Sanofi is a healthcare company engaged in the discovery, development, manufacturing, and marketing of a wide range of medicines and vaccines. The revenue for Rilzabrutinib is expected to reach an annual total of $154 mn by 2034 in the US based off GlobalDatas Expiry Model.

Stock Profile

"Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as dupixent, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products. In addition, it offers poliomyelitis, pertussis, and hib pediatric vaccines; influenza, booster, meningitis, and travel and endemic vaccines, which includes hepatitis A, typhoid, cholera, yellow fever, and rabies vaccines. The company also provides cough, cold, and flu, allergy, and pain care products, as well as physical, mental, and digestive wellness products; and offers body lotions, anti-itch products, moisturizing and soothing lotions, body and foot creams, and eczema powders. Further, it has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301 for Parkinson's disease; Blackstone Life Sciences to develop pivotal studies and clinical development program; and Seagen Inc. to design, develop, and commercialize antibody-drug conjugates for cancer. Additionally, the company has a collaboration agreement with IGM Biosciences, Inc. to develop, manufacture, and commercialize IgM antibody; Skyhawk Therapeutics, Inc to discover and develop novel small molecules; and Amunix Pharmaceuticals, Inc for T-cell engagers and cytokine therapies. It also enters in a strategic collaboration with Scribe Therapeutics Inc. to develop genome editing technologies; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was founded in 1973 and is headquartered in Paris, France."

Keywords

Are looking for the most relevant information about Sanofi? Investor spend a lot of time searching for information to make investment decisions in Sanofi. This task is often burdensome and consumes huge amounts of free time. It also leads to mistakes due to fatigue and bounded rationality. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Sanofi are: Sanofi, Buy, expect, reach, annual, total, mn, and the most common words in the summary are: sanofi, bloomberg, comment, report, market, company, news, . One of the sentences in the summary was: Jefferies Reaffirms Their Buy Rating on Sanofi.. Other searches related to this term that the AI found were: stockmarketlive, livestock, stockmarketforbeginners, thestockmarket, stockmarkettoday, stockmarkettrading, stockmarketstocks, todaystockmarket, thestockmarket, marketnews, stockmarketnews, whatisstockmarket, usstockmarket, stockmarketopen. #sanofi #bloomberg #comment #report #market #company #news.